secwatch.observer — SEC 8-K summary
======================================

Issuer:     Apyx Medical Corp (APYX)
CIK:        0000719135
Form:       8-K
Filed at:   2023-01-10T23:59:59+00:00
Accession:  0000719135-23-000002
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Apyx Medical reports preliminary Q4 revenue $12.1-12.5M (-26-28% YoY); full year $44-44.4M (-8-9%)
--------------------------------------------------------------------------------

- Advanced Energy rev Q4 $10.1-10.5M (-30-33% YoY); OEM rev $2.0M (+12% YoY).
- Full year Advanced Energy $36.4-36.8M (-14-15%); OEM $7.6M (+37%).
- CEO cites continued disruption from FDA Medical Device Safety Communication.
- Expects 2023 Advanced Energy sales growth >35% YoY; plans to submit 510(k) for new indication by Jan 2023.
- Implementing expense cuts to improve cash flow; evaluating options for liquidity enhancement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/719135/000071913523000002/0000719135-23-000002-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/719135/000071913523000002/apyx-20230110.htm
  HTML page:      https://secwatch.observer/filing/0000719135-23-000002

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer